Nanatinostat With Valganciclovir Produces Positive Topline Data in EBV+ PTCL
Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.
Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.
Nodular melanoma is a type of skin cancer that can mimic benign conditions, including blood blisters and acne. So, how do you know when to…
Immunotherapy combined with chemotherapy significantly improves progression-free survival compared to first-line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability…
During the International Myeloma Society 5th Immune Effector Cell Workshop, the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston,…
An abstract is unavailable.
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
Cancer stemness, regarded as a crucial factor in tumor development, has been recognized to involve a plastic cellular state influenced by dynamic interactions between cancer…
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
We are delighted to announce EORTC’s participation at the ESTRO Congress 2024 taking place from 3 to 7 May 2024 in Glasgow, UK.